NEW YORK, Jan. 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

http://www.reportlinker.com/p0748743/Hepatitis-Market-to-2017---Strong-Hepatitis-C-Pipeline-Large-Number-of-Strategic-Consolidations-and-Cost-Effective-Treatments-will-Drive-the-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

Summary

GBI Research's new report, "Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market", provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.

Scope

- Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.

- Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.

- Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various Phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.

- Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

List of Tables

1.1 List of Tables

Table 1: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2010 12

Table 2: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2010-2017 12

Table 3: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2010 13

Table 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2010-2017 13

Table 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 14

Table 6: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 14

Table 7: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2002-2010 16

Table 8: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2010-2017 16

Table 9: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2010 25

Table 10: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2010-2017 25

Table 11: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2010 26

Table 12: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2010-2017 26

Table 13: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 27

Table 14: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 27

Table 15: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 28

Table 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Patterns, 2010-2017 29

Table 17: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 33

Table 18: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 34

Table 19: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2010 35

Table 20: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2010-2017 35

Table 21: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 36

Table 22: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 36

Table 23: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 37

Table 24: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2010-2017 38

Table 25: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2002-2010 43

Table 26: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2010-2017 44

Table 27: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2010 45

Table 28: Hepatitis Market, Global, Revenue by Geography ($m), 2010-2017 46

Table 29: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2010 47

Table 30: Hepatitis Therapeutics Market, The US, Revenue Forecasts ($m),2010-2017 47

Table 31: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010 48

Table 32: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 48

Table 33: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern ('000s), 2002-2010 49

Table 34: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern ('000s), 2010-2017 50

Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010 55

Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2010-2017 55

Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 57

Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 57

Table 39: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern ('000s), 2002-2010 58

Table 40: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern ('000s), 2010-2017 59

Table 41: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2010 64

Table 42: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2010-2017 64

Table 43: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 65

Table 44: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 65

Table 45: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000s), 2002-2010 66

Table 46: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000s), 2010-2017 67

Table 47: Hepatitis B Therapeutics Market, Global, Pipeline, 2011 77

Table 48: Hepatitis B Vaccines Market, Global, Pipeline, 2011 80

Table 49: Hepatitis C Therapeutics Market, Global, Pipeline, 2011 83

List of Figures

1.2 List of Figures

Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2011 10

Figure 2: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2017 11

Figure 3: Hepatitis Market, Global Therapeutics and Vaccines Market, Revenues ($m), 2002-2017 12

Figure 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2017 13

Figure 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 14

Figure 6: Hepatitis Therapeutics Market, Global, Therapeutic Usage Pattern, 2002-2017 15

Figure 7: Hepatitis Therapeutics Market, Global, Diseased Population ('000s), 2002-2017 17

Figure 8: Hepatitis Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017 18

Figure 9: Hepatitis Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017 19

Figure 10: Hepatitis Therapeutics Market, Global, Prescription Population ('000s), 2002-2017 20

Figure 11: Hepatitis Therapeutics Market, Global, Branded and Generic Share (%), 2010-2017 22

Figure 12: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origin 24

Figure 13: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2017 25

Figure 14: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2017 26

Figure 15: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 27

Figure 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 28

Figure 17: Hepatitis B Therapeutics Market, Global, Diseased Population ('000s), 2002-2017 29

Figure 18: Hepatitis B Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017 30

Figure 19: Hepatitis B Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017 31

Figure 20: Hepatitis B Therapeutics Market, Global, Prescription Population ('000s), 2002-2017 32

Figure 21: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 33

Figure 22: Hepatitis B Therapeutics Market, Global, Geography Benchmarking, 2010 34

Figure 23: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2017 35

Figure 24: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 36

Figure 25: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 37

Figure 26: Hepatitis C Therapeutics Market, Global, Diseased Population ('000s), 2002-2017 39

Figure 27: Hepatitis C Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017 40

Figure 28: Hepatitis C Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017 41

Figure 29: Hepatitis C Therapeutics Market, Global, Prescription Population ('000s), 2002-2017 42

Figure 30: Hepatitis C Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 43

Figure 31: Hepatitis C Therapeutics Market, Global, Geography Benchmarking, 2010 44

Figure 32: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2017 45

Figure 33: Hepatitis Market, Global, Geography Benchmarking, 2010 and 2017 46

Figure 34: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2017 47

Figure 35: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017 48

Figure 36: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern, 2002-2017 49

Figure 37: Hepatitis Therapeutics Market, The US, Diseased Population ('000s), 2002-2017 51

Figure 38: Hepatitis Therapeutics Market, The US, Treatment Seeking Population ('000s), 2002-2017 52

Figure 39: Hepatitis Therapeutics Market, The US, Diagnosed Population ('000s), 2002-2017 53

Figure 40: Hepatitis Therapeutics Market, The US, Prescription Population ('000s), 2002-2017 54

Figure 41: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2017 55

Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 57

Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern, 2002-2017 58

Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population ('000s), 2002-2017 60

Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population ('000s), 2002-2017 61

Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population ('000s), 2002-2017 62

Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population ('000s), 2002-2017 63

Figure 48: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2017 64

Figure 49: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 65

Figure 50: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2002-2017 66

Figure 51: Hepatitis Therapeutics Market, Japan, Diseased Population ('000s), 2002-2017 68

Figure 52: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population ('000s), 2002-2017 69

Figure 53: Hepatitis Therapeutics Market, Japan, Diagnosed Population ('000s), 2002-2017 70

Figure 54: Hepatitis Therapeutics Market, Japan, Prescription Population ('000s), 2002-2017 71

Figure 55: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 73

Figure 56: Hepatitis Market, Global, R&D Pipeline by Phase (%), 2011 73

Figure 57: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 75

Figure 58: Hepatitis B Vaccines Market, Global, R&D Pipeline by Phase (%), 2011 79

Figure 59: Hepatitis C Therapeutics Market Global, R&D Pipeline by Phase (%), 2011 81

Figure 60: Hepatitis B and Hepatitis C Therapeutics Market, Global, Market Share of Top Players (%), 2010 95

Figure 61: Hepatitis Vaccines Market, Global, Market Share of Top Players (%), 2010 96

Figure 62: Hepatitis Market, Merck & Co., Inc., SWOT Analysis, 2011 97

Figure 63: Hepatitis Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2011 99

Figure 64: Hepatitis Market, GlaxoSmithKline plc, SWOT Analysis, 2011 100

Figure 65: Hepatitis Therapeutics and Vaccines Market, Global, M&A Deals by Geography (%), 2011 102

Figure 66: Hepatitis Therapeutics and Vaccines Market, M&A Deals by Type (%), 2011 103

Figure 67: Hepatitis Market, Global, Major Licensing Agreements by Indication (%), 2011 105

Figure 68: Hepatitis Market, Global, Major Co-Development Deals by Indication (%), 2011 108

Figure 69: GBI Research Market Forecasting Model 113

Companies Mentioned

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

To order this report:

Therapy Industry: Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com